Skip to main content
. Author manuscript; available in PMC: 2015 Jun 13.
Published in final edited form as: Kidney Int. 2009 Oct 7;76(12):1277–1283. doi: 10.1038/ki.2009.384

Table 2.

HLA antibody and biopsy data for patients with high and low anti-PKCζ levels

Characteristic Patients
with high
anti-PKCζ
titers		 Patients
with low
anti-PKCζ
titers		 P-value
Number of patients 3 12
Allograft survival 33.3% 100% 0.002
Biopsy Banff score 0.63
 1a 1 3
 1b 2 6
 2a 0 3
Antibody-mediated rejection 0% 33% 0.24
Dense CD20-positive clusters 33.3% 58.3% 0.44
Presence of donor-specific antibody
at AR		 66.7% 50% 0.60
Presence of non-donor-specific
antibody HLA antibodies at AR		 66.7% 41.7% 0.44
Presence of any HLA antibody at AR 100% 75% 0.33

AR, acute rejection; HLA, human leukocyte antigen; PKCζ, protein kinase C-ζ Association of HLA antibody and biopsy factors with anti-PKCζ levels. P-values <0.05 represent a significant association between high anti-PKCζ and the respective variable.